Rallybio Corporation (NASDAQ:RLYB) shares are trading higher after the company announced a collaboration with Johnson & Johnson (NYSE:JNJ) to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT).  FNAIT is a rare immune disorder that occurs when the baby’s platelets are attacked and destroyed by the mother’s immune cells in her bloodstream. In addition, Rallybio received an equity investment of $6.6 million from Johnson & Johnson Innovation. Rallybio is developing RLYB212, a human monoclonal anti-HPA-1a antibody designed to prevent pregnant individuals from alloimmunizing.  Rallybio is on track to initiate ...